Exanta - Oral Direct Thrombin Inhibitor for the Prevention and Treatment of Venous Thromboembolism
Key Data:
Drug (brand/generic)
Exanta (ximelagatran)
Company/licensee
AstraZeneca
Therapy class
Anticoagulant
Product description
Direct thrombin inhibitor
Current indication
VTE prophylaxis following orthopaedic surgery
Market sector
Cardiovascular
Development status
Withdrawn from the market
